Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate
Crossref DOI link: https://doi.org/10.1007/s00280-017-3360-3
Published Online: 2017-07-10
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hussaini, Azra
Olszanski, Anthony J.
Stein, Cy A.
Bosch, Bill
Nemeth, Paul
Funding for this research was provided by:
Churchill Pharmaceuticals LLC
License valid from 2017-07-10